U.S. Healthcare Services Stock News

Recent quarterly results from Bio-Techne (TECH) came in ahead of earnings and revenue forecasts, and were followed by fresh institutional buying and portfolio additions that put renewed attention on the life sciences supplier. See our latest analysis for Bio-Techne. Despite the upbeat quarter and renewed institutional interest, the 30 day share price return of a 15.15% decline and 1 year total shareholder return of an 18.27% loss show momentum has been weak, with pressure building across both...

In March 2026, Adaptive Biotechnologies reported fourth-quarter 2025 results that beat analyst expectations, with revenue growth led by its Minimal Residual Disease (MRD) business, while several senior executives sold shares largely to cover tax obligations linked to vested equity awards. This combination of stronger MRD performance and insider sales tied mainly to tax withholding offers insight into how operational momentum and routine executive transactions can coexist without necessarily...

Recently, Boise Cascade reported quarterly earnings and revenue that came in ahead of analyst expectations, even as it faced typical seasonal softness and broader market headwinds in its building products markets. The company also highlighted progress on its Thorsby i-line expansion, disciplined operational controls, and lean channel inventories, which together point to a tighter, more efficient operating base for its engineered wood and distribution businesses. Next, we'll examine how this...

In March 2026, Revolve Group, Inc. launched Revolve Los Angeles, its first namesake fashion house, debuting a XXS–XL collection priced around US$200–US$3,500 and sold exclusively on Revolve and FWRD. The move expands Revolve’s in-house brand portfolio into higher-end, couture-influenced ready-to-wear, potentially deepening customer engagement around luxury, Los Angeles-inspired fashion. Next, we’ll examine how Revolve Los Angeles, as a higher-end in-house label, could influence Revolve...

Earlier this month, Hess Midstream LP announced that its Board authorized a share repurchase program and entered into an agreement with JPMorgan Chase Bank to buy back up to US$42 million of Class A shares, funded through its existing revolving credit facility, with repurchased shares to be cancelled and final settlement expected by March 2026. This accelerated share repurchase arrangement not only reduces the public float but also underscores management’s willingness to use balance sheet...

In recent days, Moelis & Company reported strong Q4 earnings and highlighted its strongest coverage platform to date, with management emphasizing momentum and long-term value creation. At the same time, several major banks reiterated neutral views on Moelis, revealing a tension between upbeat internal commentary and cautious external assessments. Next, we'll examine how upbeat earnings alongside cautious analyst sentiment may influence Moelis' existing investment narrative around growth...

In early March 2026, U.S. Bancorp expanded its funding options with a series of new senior unsecured fixed-rate notes maturing between 2031 and 2046, while also declaring regular quarterly and semi-annual dividends on its common and multiple preferred share classes payable on April 15, 2026. The creation of a President of Emerging Affluent Wealth Management role, alongside fresh bond issuance and an updated universal shelf registration, points to a coordinated push to deepen relationships...

In recent days, Department of Justice documents revealed that Ubiquiti’s networking equipment was used for communications and surveillance on Jeffrey Epstein’s private island, drawing public and regulatory attention to the company’s role. This association creates a new layer of reputational and legal risk for Ubiquiti, complicating an investment story previously focused on balance sheet strength and earnings momentum. We’ll now examine how this emerging reputational and regulatory risk...

In recent days, Opendoor Technologies reported Q4 revenue that exceeded analyst expectations while guiding to a roughly 10% year-on-year revenue decline for Q1 and an adjusted EBITDA loss. Management highlighted progress in unit economics, growth of its low-capital Cash Plus offering, cost reductions, and a new 4.99% beta mortgage program that together point to an evolving, more flexible business model. Next, we’ll examine how Opendoor’s stronger-than-expected Q4 revenue and improved unit...

On March 10, 2026, Amalgamated Financial Corp reported fourth-quarter 2025 earnings with earnings per share of $0.91, matching analyst expectations, while quarterly revenue of $87.91 million modestly exceeded forecasts. On the same day, Executive Vice President and Chief Legal Officer Mandy Tenner sold 776 shares under a Rule 10b5-1 plan, adding to a year of insider selling that raises questions about how leadership is managing personal holdings alongside solid operating results. Next,...

Ascendis Pharma A/S recently reported two-year data from its pivotal ApproaCH Trial, showing that once-weekly TransCon CNP (YUVIWEL) maintained consistent improvements in growth and body proportionality in children with achondroplasia, with a generally well-tolerated safety profile and strong trial retention. These longer-term results reinforce YUVIWEL’s clinical profile shortly after its U.S. approval for pediatric achondroplasia and ahead of a key European regulatory decision expected...

Why the leadership reshuffle at Playtika Holding (PLTK) matters for shareholders Playtika Holding (PLTK) is reshaping its senior ranks, with long serving President and CFO Craig Abrahams set to depart on April 1, 2026, and responsibilities shifting to existing insiders. Board chair Robert Antokol will add the President role. Senior finance leader Tae Lee will step in as acting CFO after several years overseeing corporate finance and investor relations. See our latest analysis for Playtika...

Netskope (NTSK) is back in focus after launching its Netskope One AI Security suite, alongside fresh earnings results and new healthcare integrations that together highlight how it is positioning around enterprise AI security. See our latest analysis for Netskope. Despite the launch of Netskope One AI Security and new healthcare integrations, Netskope’s short term share price return has been mixed. The 7 day share price return is 20.75% and the 90 day share price return is 51.40%, which...

The Trump administration previously issued an executive order under the Defense Production Act directing Sable Offshore to restart its long-idled Santa Ynez offshore unit and associated California pipelines, aiming to bolster fuel supplies during the conflict with Iran. This federal push, alongside ongoing court challenges and questions over permitting and safety, has turned Sable Offshore into a high-profile test case for how far Washington can go in overriding state-level environmental...

H2O America recently completed a follow-on equity offering of US$608.70 million, issuing 11,484,824 common shares at US$53 each with a US$1.7225 discount per share to help fund an acquisition. At the same time, Baird initiated coverage on H2O America with an Outperform rating, signaling increased institutional attention just as the company raises fresh capital for expansion. Next, we’ll explore how this sizable equity raise to fund an acquisition could reshape H2O America’s previously...

Willis Towers Watson (WTW) shares are in focus after the company expanded its GB Affinity technology ecosystem through a partnership with Qover, targeting embedded insurance solutions that are integrated directly into customer journeys across multiple sectors. See our latest analysis for Willis Towers Watson. Despite the Qover partnership putting the focus on Willis Towers Watson’s technology capabilities, the shares trade at US$289.54 after a 12.2% decline in the 3 month share price return,...

InnovAge Holding (INNV) has just been upgraded to a higher Zacks rank, supported by rising earnings estimate revisions and a hammer chart pattern that points to improving sentiment and renewed attention on the stock. See our latest analysis for InnovAge Holding. At a share price of $8.39, InnovAge Holding has seen short term share price pressure, with a 7 day share price return of a 4.22% decline, alongside strong recent momentum reflected in a 90 day share price return of 51.17% and a 1 year...

VEON (VEON) shares reacted to fresh fourth quarter and full year 2025 results, where record digital revenue growth, higher group revenue and EBITDA, a new share buyback program, and 2026 guidance drew investor attention. See our latest analysis for VEON. VEON’s share price jumped 14.2% on the day of the results, even though the 30 day and year to date share price returns of 3.5% and 4% point to fading short term momentum. At the same time, the 3 year total shareholder return of about 215%...

Apollo Global Management has launched the CG Apollo Global Diversified Credit LTAF, a newly FCA‑authorized multi-sector private credit fund offering UK defined contribution schemes access to a diversified global credit portfolio in a semi-liquid format. This fund is the first sub-fund in Apollo’s broader Private Markets LTAF umbrella and extends its push to bring institutional-grade private market retirement solutions to defined contribution plans across the UK, US and Europe. We’ll now...

Why MBX Biosciences is on investors’ radar today MBX Biosciences (MBX) has attracted attention after a recent move in its share price, with the stock now around $28 following mixed short term returns, including a decline over the past month and a modest gain over the past 3 months. See our latest analysis for MBX Biosciences. That recent pullback, with a 30 day share price return of around 26% decline and year to date share price return of around 8% decline, contrasts sharply with a very...

Earlier in March 2026, AllianceBernstein Holding reported that preliminary assets under management rose to US$880 billion in February from US$875 billion in January, mainly due to market appreciation despite modest net outflows. The firm also reported that private markets assets under management reached US$82 billion, a year-over-year increase described as 18%, alongside more than US$140 billion in annual sales even as active equities saw net outflows. We’ll now consider how this fresh...

Why Citizens Financial Group Is On Investors’ Radar Citizens Financial Group (CFG) has attracted attention after a roughly 14% decline over the past month, prompting investors to reassess the bank’s US$55.64 share price against its recent financial profile. See our latest analysis for Citizens Financial Group. That recent 14% one month share price decline sits against a 41.15% one year total shareholder return and a 101.79% three year total shareholder return, so recent momentum looks weaker...

Event-driven snapshot of CBIZ CBIZ (CBZ) is on investors’ radar after recent share price volatility, with the stock showing negative returns over the past month and past 3 months, prompting fresh interest in how its fundamentals line up. See our latest analysis for CBIZ. At a share price of $26.12, CBIZ has seen momentum fade, with a 30 day share price return of 6.18% and a year to date share price return decline of 48.58%, contributing to a 63.27% drop in 1 year total shareholder return. If...

Infleqtion stock at a glance Infleqtion (INFQ) has drawn investor attention after a period of weaker recent returns, with the share price down 5.6% over the past day and 26.2% over the past month. See our latest analysis for Infleqtion. The recent 41.2% year-to-date share price return decline, including a 26.2% drop in the last 30 days, suggests momentum has been fading as investors reassess Infleqtion's risk and growth profile in quantum computing. If Infleqtion's recent swings have you...